key: cord-0988630-xuz5e22f
authors: Dubé, Charlotte; Paris-Robidas, Sarah; Primakova, Iryna; Destexhe, Eric; Ward, Brian J.; Landry, Nathalie; Trépanier, Sonia
title: Lack of Effects on Female Fertility or Pre- and Postnatal Development of Offspring in Rats after Exposure to AS03-adjuvanted Recombinant Plant-Derived Virus-Like Particle Vaccine Candidate for COVID-19
date: 2021-11-24
journal: Reprod Toxicol
DOI: 10.1016/j.reprotox.2021.11.006
sha: 9487ea617955e11a514d68bf7ad8a0d436291f0b
doc_id: 988630
cord_uid: xuz5e22f

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection resulting in the coronavirus disease 2019 (COVID-19) has afflicted tens of millions of people in a worldwide pandemic. A recently developed recombinant Plant-Derived Virus-Like Particle Vaccine candidate for COVID-19 (CoVLP) formulated with AS03 has been shown to be well-tolerated and highly immunogenic in healthy adults. Since the target population for the vaccine includes women of childbearing potential, the objective of the study was to evaluate any untoward prenatal and postnatal effects of AS03-adjuvanted CoVLP administered intramuscularly to Sprague-Dawley female rats before cohabitation for mating (22 and 8 days prior) and during gestation (Gestation Days [GD] 6 and 19). The embryo-fetal development (EFD) cohort was subjected to cesarean on GD 21 and the pre/post-natal (PPN) cohort was allowed to naturally deliver. Effects of AS03-adjuvanted CoVLP was evaluated on pregnant rats, embryo-fetal development (EFD), during parturition, lactation and the development of the F1 offspring up to weaning Vaccination with AS03-adjuvanted CoVLP induced an antibody response in F0 females and anti-SARS-CoV-2 spike-specific maternal antibodies were detected in the offspring at the end of the gestation and lactation periods. Overall, there was no evidence of untoward effects of AS03-adjuvanted CoVLP on the fertility or reproductive performance of the vaccinated F0 females. There was no evidence of untoward effects on embryo-fetal development (including teratogenicity), or early (pre-weaning) development of the F1 offspring. These results support the acceptable safety profile of the AS03-adjuvanted CoVLP vaccine for administration to women of childbearing potential.

In December 2019, a series of severe atypical respiratory disease cases occurred in Wuhan, China and a novel coronavirus named SARS-CoV-2 was rapidly identified as the causative agent of coronavirus disease 2019 [1, 2] . SARS-CoV-2 virions consist of a helical nucleocapsid, formed by association of nucleocapsid phosphoproteins with viral genomic RNA that is surrounded by a lipid bilayer, into which three structural proteins are In this case, the newly synthesized full-length S proteins trimerize and move to lipid rafts where they spontaneously assemble into viruslike particles (VLPs) that 'bud' off the surface of the plant cell [3] . The S proteins in plantderived coronavirus-like particles (CoVLP) are in a stabilized, prefusion conformation that resembles the native structure seen on SARS-CoV-2 virions. The prefusion form of S protein is preferred as a vaccine antigen since it contains several epitopes in the receptor binding domain (RBD) that are primary targets for neutralizing antibodies. Moreover, a study of the closely-related Middle-Eastern Respiratory Syndrome virus (MERS) suggests that the prefusion state of the S protein is a potent immunogen with dose-sparing properties [4] .

In the pandemic context, CoVLP has been formulated with the immunostimulatory Adjuvant System AS03 to enhance the immune response [5] [6] [7] and as a consequence to reduce the amount of antigen needed per dose (AS03-adjuvanted CoVLP). The Adjuvant System AS03, an α-tocopherol-containing oil-in-water emulsion, has been used in the licensed pandemic A/H1N1pdm09 influenza vaccines Arepanrix H1N1 (in Canada) and

Pandemrix (in Europe), as well as in other licensed (Q Pan H5N1, in the USA) or candidate vaccines [8] . Reproductive and developmental toxicity studies in rats revealed no evidence of toxicity of AS03 alone or in combination with influenza antigens [9] . The safety of AS03-adjuvanted CoVLP candidate vaccine has been evaluated in several nonclinical studies in mice (unpublished data), nonhuman primates [10] and clinical studies in adults (Phase 2/3 clinical trial (NCT04636697) ongoing) in which AS03-adjuvanted CoVLP was administered via intramuscular (IM) route. The results of the Phase 1 clinical trial showed that this vaccine has an acceptable safety profile and induces both humoral and cellular immune responses [11] . Since the target population for the vaccine includes women with childbearing potential, a nonclinical developmental and reproductive toxicity (DART) study was required to support the clinical development and licensure of the vaccine [12] .

The results of the DART study are reported herein and demonstrate no untoward effects of AS03-adjuvanted CoVLP in F0 females, fetuses or F1 offspring. This is one of the first detailed descriptions of a DART assessment following the administration of an AS03adjuvanted anti-COVID VLP vaccine. To our knowledge, animal DART data are currently available only for the Pfizer/ BioNTech COVID-19 vaccine in rats, which did not reveal any safety concerns [13] .

The study was conducted at Charles River Laboratories Montreal ULC (Senneville, Québec, Canada) and in accordance with the recommendations of international guidelines applicable on the development of vaccine and considerations for developmental toxicity study of the EMA [14] , ICHS5 (R3) [15] , OECD [16] , FDA [17] and WHO [18] .

The study was conducted in accordance with the OECD Principles of Good Laboratory Practices (GLP) [19] and as accepted by Regulatory Authorities throughout the European Union, USA (FDA), Japan (MHLW), and other countries that are signatories to the OECD Mutual Acceptance of Data Agreement; and in accordance with Charles River Laboratories Montreal ULC (Senneville, Québec, Canada) standard operating procedures (SOPs). The study was monitored by Charles River Quality Assurance (QA) personnel to ensure the facilities, equipment, personnel, methods, practices, records, and controls used were in conformance with GLP standards for the conduct of nonclinical studies. The QA personnel also reviewed the study protocols and amendments, conducted inspections at intervals considered adequate to assure the integrity of the study, and audited the final report to assure that it accurately described the methods and SOPs followed and that reported results were an accurate reflection of the raw data.

The full-length S glycoprotein of SARS-CoV-2, strain hCoV-19/USA/CA2/2020, corresponding in sequence to nucleotides 21563 to 25384 from EPI_ISL_406036 in GISAID database (https://www.gisaid.org/) was expressed in Nicotiana benthamiana plants as previously described [3] . The S protein was modified with R667G, R668S and R670S substitutions at the S1/S2 cleavage site to increase stability, and K971P and V972P substitutions to stabilize the protein in prefusion conformation. The signal peptide was replaced with a plant gene signal peptide and the transmembrane domain (TM) and cytoplasmic tail (CT) of S protein was also replaced with TM/CT from Influenza H5 A/Indonesia/5/2005 to increase VLP assembly and budding. The self-assembled VLPs bearing S protein trimers were isolated from the plant matrix and subsequently purified using a process similar to that described for Medicago's plant-derived influenza VLP vaccine candidates [20] .

The AS03 Adjuvant System, an oil-in-water emulsion containing 11.86 mg DL-αtocopherol, 10.69 mg squalene and 4.86 mg Polysorbate 80 per human dose of 0.25 mL, was supplied by GSK, (Rixensart, Belgium) and was used as recommended by the manufacturer. The control article was phosphate buffered saline (PBS) solution with Polysorbate 80. On each dosing day, CoVLP was diluted with PBS to achieve the appropriate concentration and then mixed in a 1:1 (volume:volume) ratio with adjuvant prior to administration.

Sprague-Dawley Crl:CD rats were supplied by Charles River (Raleigh, North Carolina, USA). Female rats were approximately 7 weeks of age at the start of the study. In summary, animals were maintained under standard laboratory conditions (lighting: 12 / 12 hours, temperature: 22 ± 3°C, relative humidity: 30 to 70%) with certified rodents pellet feed (Lab Diet Certified Rodent Diet 5002) and had ad libitum access to water treated by reverse osmosis. Animals were acclimated for at least 15 days to the laboratory environment prior to initiation of dosing. F0 females were group-housed, except during cohabitation for mating, in polycarbonate cages with bedding. After a 22-day pre-mating dosing period, each F0 female was cohabited on a 1:1 basis with a untreated proven breeder male of the same strain for up to 14 days. At the end of the mating period, females failing to show signs of mating were newly paired with a new proven breeder male for up to 7 additional days.

Females with confirmed presence of spermatozoa observed in a smear of the vaginal lavage and/or a copulatory plug observed in situ were considered to have mated. On the day mating was confirmed (referred as GD 0), the female was transferred back to group housing. On GD 20, PPN Phase F0 females were single housed until parturition at which time dams were housed with their litter until termination.

All procedures involving the care and use of animals were performed in accordance with the Canadian Council on Animal Care, the Guide for the Care and Use of Laboratory The overall design of the DART study is illustrated in Figure 1 . Animals assigned to the study were selected based on a screening for the presence of fulllength trimeric S protein to minimize bias during immunogenicity analyses. Sprague-Dawley female rats (n = 92) were randomly assigned either to a placebo group (n = 46) or to AS03-adjuvanted CoVLP group (n = 46) using a computer-based randomization program balanced by body weight. Once mated, females were allocated to either a cesarean delivery cohort (embryofetal development phase EFD, n=22/group) euthanized on gestation day GD 21 or to a natural delivery cohort (pre-and postnatal phase PPN, n=24/group) and allowed to rear offspring until postnatal day PND 21. Animals were administered AS03-adjuvanted CoVLP or placebo 22 days prior to cohabitation for mating (study day SD 1), 7 days prior cohabitation (SD 15), on GD 6 and GD 19. The chosen administration regimen allowed induction of peak immune response at mating and during the critical phases of pregnancy (i.e., the period of organogenesis) and maximized exposure to maternal antibodies throughout the embryonic, fetal, and early postnatal periods. On each administration day, each female rat received 0.2 mL of either AS03-adjuvanted CoVLP (CoVLP dose of 3 µg) or phosphate buffered saline by IM injection at one injection site either in the lateral compartment of the right or left thigh muscles. The F1 offspring did not receive any injections. As per FDA Guidance to the industry [17] , a 3 µg dose of CoVLP was deemed sufficient to assess its safety when administered with AS03 since the antigen dose exceeded the human dose on a body weight basis by 160-fold (based on 3 µg

CoVLP for a 0.250 kg rat and 3.75 µg CoVLP for a 50 kg woman), while the dose of AS03 exceeded the human dose by 80-fold (based on 0.1 mL AS03 for a 0.250 kg rat and 0.25 mL AS03 for a 50 kg woman). The dose administered to animals was confirmed by dose formulation analyses at the time of the first (SD 0) and last (GD 19) administrations.

Observations for moribundity and mortality were performed twice daily during pre-mating, gestation, and lactation. Clinical observations were performed at least once daily. Each injection site was observed for erythema (redness) and edema (swelling) prior to dosing and daily for 7 days following each dosing. Erythema was scored as 1 for the presence of skin redness and edema was scored as 1 for area around of exposure and 2 for area beyond area of exposure. Body weights and food consumption were recorded throughout the study.

Estrous cycles were determined for at least 14 consecutive days before initiation of dosing 

Blood samples were collected from all F0 female rats by jugular venipuncture prior to the first dose administration for prescreening, baseline antibody levels (SD -1), and on SD 14, and from the abdominal aorta (terminal procedure) on GD 21 (EFD cohort only) and PND 21 (PPN cohort only). On GD 21, the EFD F0 dams were deeply anesthetized using isoflurane, the abdomen and uterus were opened to expose the fetuses and blood samples were collected by cardiac puncture from approximately 50% of the live fetuses in each litter using capillary tubes, pooled per litter into serum separator tubes and processed.

Following completion of the fetal blood collection, blood samples were collected by abdominal aorta puncture from the anesthetized dams. Blood was also collected from 1 male and 1 female pups from each litter at terminal euthanasia on PND 21. All samples were centrifuged, and the resultant sera were separated and frozen immediately on dry ice and transferred in a -80°C freezer until analyzed.

EFD F0 female rats and the PPN F0 females and their offspring were euthanized and necropsied on GD 21 and PND 21, respectively. F0 females and F1 offspring were euthanized by exsanguination from the abdominal aorta under isoflurane anesthesia.

Fetuses selected for immunogenicity analysis were euthanized by cardiac puncture and the remaining animals were euthanized by subcutaneous administration of an euthanyl/lidocaine mixture. All F0 and F1 animals retained on the study were subjected to a complete necropsy at termination, which included evaluation of the carcass and musculoskeletal system; all external surfaces and orifices; cranial cavity and external surfaces of the brain; and thoracic, abdominal, and pelvic cavities with their associated organs and tissues. The gravid uteri of the EFD F0 female rats were examined for number and distribution of corpora lutea, implantation sites, live and dead fetuses and early/late resorptions as well as any abnormalities in placentae (size, color and shape). At cesarean, fetuses were removed from the uterus and retained for examination (body weight, sex, external, visceral and skeletal abnormalities). Approximately half of the fetuses were selected for visceral examination using a modification of the microdissection techniques of Staples [21] . The heads of these fetuses were removed and fixed in Harrison's solution for examination by the technique of Wilson [22] . The remaining fetuses were selected immunogenicity blood collection and for skeletal examination after staining with alizarin red S [23, 24] . Fetal observations were classified as either malformations (rare structural defects thought to be life threatening or of major physiological consequence) or variation (commonly minor abnormalities, defects or alternative forms that are of no known major physiological consequence). For PPN F0 dams, the number of implantation site scars were recorded at euthanasia.

Specific-IgG antibodies to full-length trimeric S protein were measured in the serum samples using a qualified semi-quantitative ELISA method at Charles River Facility. Sera were diluted 1/100 (minimum required dilution or MRD) with EZ Block and loaded on a microtiter plate coated with recombinant full-length trimeric S protein from SARS-CoV-2/Wuhan/2019 (Immune Technology, New York, NY). Rat anti-SARS-CoV-2 S protein IgG antibodies present in the rat serum samples bound to the immobilized antigen. The detection of bound anti-SARS-CoV-2 S protein IgG was performed using a goat anti-rat IgG horseradish peroxidase (HRP) conjugated secondary antibody (Jackson ImmunoResearch, West Grove, PA). The bound HRP metabolized tetramethylbenzidine, subsequently added to each well, to generate a chromophore, for which the absorbance at 450 nm was determined using a spectrophotometer. The absorbance of the chromophore correlated with the level of rat anti-S protein IgG antibodies present in the samples.

The descriptive statistics and statistical comparisons were performed where appropriate.

Numerical data were analyzed according to occasion and, as applicable, sex and/or by litter.

Levene's test was used to assess the homogeneity of group variances. test followed by a Dunn's test. For incidence, Fisher's exact test or Chi 2 test were used to conduct pairwise group comparisons of interest. For immunogenicity analyses, data were Log2-transformed and pairwise comparisons were performed for each study day using the Student t-test. All statistical analyses were performed using Provantis and/or SRS (testing facility in-house application built with SAS) and/or in-house reporting software Nevis 2012 (using SAS) and statistical significance was set at p < 0.05 and reported at the 1% and 5% levels (unless otherwise noted).

The presence of anti-S IgG antibodies was assessed in serum from maternal (SD 14, GD for placebo and n=21 for CoVLP + AS03) and PPN Phase (PND21; n=22 for placebo and n=21 for CoVLP + AS03, except for male pups n=20). Half of the minimum required dilution (MRD) of the method was assigned to non-responders (i.e., 50 for IgG titers) for GMT calculation purposes. In each panel, statistical comparisons were performed using Student's t-test between Log2-transformed IgG titers of the control and the vaccine groups for each study day, ** p < 0.01. Estrous cyclicity (the number of days in estrus, the number of cycles or the mean cycle length of the observed cycles) was evaluated between SD 1 to SD 23 for all F0 females,

i.e. in females vaccinated twice (SD 1 and SD 15) during the pre-mating period. Results (Table 1) showed that the administration of AS03-adjuvanted CoVLP did not affect estrous cyclicity of the vaccinated F0 females. The reproductive parameters (Table 2 ) and the ovarian uterine data (Table 3) for the AS03-adjuvanted CoVLP treated females were comparable to the placebo group. 

No significant differences in number of fetuses per litter (Table 3) , sex ratio ( Figure 4A) or mean female and male fetal body weights ( Figure 4B) were noted between the AS03adjuvanted CoVLP treated females and the placebo group. Dunnett's test. No significant differences were detected (p > 0.05) and annotated on the graphs as ns.

Observations of fetal external malformations ( Table 4) (Table 5 ) consisting of Situs Inversus of the thorax was noted in the AS03-adjuvanted CoVLP group at a very low incidence. A small eye lens was noted in the placebo group. Skeletal malformations (Table 6 ) consisting in fused rib occurred on average in less than 1% of the fetuses per litter of the AS03-adjuvanted CoVLP group and this finding was within the normal historical control range and thus was not considered treatment-related.

Visceral variations consisting of small renal papilla and convolution/dilatation of the ureter were observed in AS03-adjuvanted CoVLP and/or placebo groups at low incidence. Some skeletal variations (Table 6 ) also occurred either in the AS03-adjuvanted CoVLP or placebo groups. The incidence of each observation was within historical control range of the testing facility, and these findings were considered to be of a spontaneous nature and were therefore not considered related to the administration of the vaccine candidate [25] . 

The administration of AS03-adjuvanted CoVLP had no effect on F0 generation dams' females ranged from 81.3% to 100.0%. Moreover, the survival index up to PND 21 was 100% in both groups (Table 7) . 100.00 ± 0.00 100.00 ± 0. administration of AS03-adjuvanted CoVLP to the F0 generation dams ( Figure 5 ). The few minor clinical observations noted during the pre-weaning period for the male and female pups in this group were also observed in the placebo group or occurred at a low incidence and, therefore, were not considered to be treatment related. 

Several health authorities such as the WHO have advocated for the use of COVID-19

vaccines during pregnancy since pregnant women are at elevated risk of developing severe illness and SARS-CoV-2 infection has been associated with adverse pregnancy outcomes [26, 27] . Therefore, to support the use of the AS03-adjuvanted CoVLP vaccine candidate in women of childbearing potential and pregnant women, the potential untoward effects of AS03-adjuvanted CoVLP on reproduction and development (embryo-fetal and preweaning) were evaluated in female rats following repeated administrations prior to mating and during gestation.

Overall, the results of the current study showed no systemic toxicity in AS03-adjuvanted

CoVLP treated females and only transient local signs of inflammation (edema) with associated macroscopic findings were observed at the injection sites of most animals. Local reactogenicity is frequently observed following the intramuscular administration of vaccines adjuvanted with AS03 [9, [28] [29] [30] , and is indicative of a local inflammatory process and the initiation of an innate and adaptive immune response [31] . The AS03-adjuvanted [32] .

In pregnant women, it has been reported that the developing fetus can sometimes be infected by SARS-CoV-2 in utero (ie: vertical transmission) as demonstrated by positive PCR results from amniotic fluid, umbilical cord blood, or neonatal blood shortly after birth [33, 34] . Although the short-and long-term impact of fetal/neonatal SARS-CoV-2 infection are currently unknown, elevated levels of inflammatory cytokines were detected in the serum of neonates born of SARS-CoV-2 infected women [35] .

Because many of the physiologic changes associated with pregnancy make pregnant women more susceptible to severe illness with respiratory viruses such as influenza [36] [37] [38] and COVID-19 [27] , the benefit/risk of the vaccination generally far exceeds the potential consequences of developing such infections during pregnancy. Although the clinical manifestations of COVID-19 in pregnant women are generally similar to those in non-pregnant adults [39] , pregnant women are at increased risk of severe illness [27] associated with adverse pregnancy events such as preterm birth, fetal vascular malperfusion, and premature fetal membrane rupture [26] . These women are also more susceptible to COVID-related thromboembolic complications due to higher levels of circulating coagulation factors during pregnancy [40] . Pre-eclampsia and COVID-19 also have overlapping features including high blood pressure, thrombocytopenia (i.e. low platelet count), and immune dysregulation which can complicate timely diagnosis of the former condition [41] In the context of COVID-19 pandemic and the elevated risk of serious outcomes in pregnancy [42] , it is crucial for pregnant women to be adequately protected against viral infection. Interestingly, data available suggest that antibodies induced by natural SARS-CoV-2 infection during pregnancy may not confer the same neutralizing potential [43] and be less efficiently transferred to the fetus compared to those generated by vaccination [44] .

In the current study, we reported placental transfer of SARS-CoV-2-specific IgG to the fetuses at ~15% of the levels seen in the dams. Even though no direct correlation between the placental transfer rate of rat and human can be made, this observation is reassuring since the placenta is the major route by which maternal antibodies are transferred to the fetus/neonate in humans [45] in contrast to rats in which lactation is the principal mechanism of such transfer [46] . This observation suggests that significant transfer of maternal antibodies to the fetus is likely to occur following vaccination of pregnant women.

While the acquisition of maternal antibodies by human infants via breastmilk is more limited than placental transfer, anti-SARS-CoV-2 antibodies are present in women who have natural infection [47] [48] [49] [50] and would be expected to be even higher following administration of vaccines that elicit strong neutralizing antibody responses like AS03adjuvanted CoVLP [51] . The general benefits of breastfeeding are well understood [48] [49] [50] and would be further enhanced by the presence of antibodies in the breastmilk that may have a protective effect for the recipient infant against SARS-CoV-2 infection [52] . In the current study, the level of serum IgG antibodies in the pups on PND 21 was ~ 70% of the level measured in the dams at the same time. Even though antibody levels were not measured directly in the breastmilk, these results strongly suggest successful antibody transfer during lactation, which is the expected route for rodents. It is noteworthy that the exposure of the fetus and pups to the very high levels of maternal anti-SARS-CoV-2 IgG antibodies directed against the S protein induced by AS03-adjuvanted CoVLP was not associated with any sign of toxicity during development.

Based on the evidence outlined above, most authorities agree that pregnant women [42] should be included in the priority populations for SARS-CoV-2 vaccination [53] . Although safety data are rapidly accumulating in pregnancy registries for a small number of widely deployed vaccines [54] and that several studies of SARS-CoV-2 vaccine use in pregnancy are on-going, we are not aware of any human trials that have demonstrated fetal and neonatal safety with any COVID-19 vaccines. The data currently available from animal developmental and reproductive toxicity studies are also very limited but have not suggested any safety concerns with regards to female fertility, fetal, embryonal, or postnatal development [13, 32] .

The current study was conducted according to regulatory guidelines to support the use of AS03-adjuvanted CoVLP vaccine in women of childbearing potential and during pregnancy. Results presented shows that the administration of the AS03-adjuvanted

CoVLP to female Sprague-Dawley rats twice before mating and twice during gestation did not result in any measurable developmental or reproductive toxicity. There was no effect on mating, fertility, pregnancy, parturition, maternal care of offspring, or prenatal or postnatal offspring viability, survival, growth, or development. A robust immune response was confirmed in F0 female rat prior to mating and at the end of gestation and lactation.

High levels of antibodies were also detected in fetuses and F1 offspring. Overall, these results suggest an acceptable safety profile of AS03-adjuvanted CoVLP vaccine for administration in women of childbearing potential.

The study was sponsored by Medicago Inc. The authors would like to acknowledge Cindy Gutzeit from GSK and Louise Pouliot from Charles River for critical review of the manuscript. The authors also wish to acknowledge all the Medicago employees and their contractors for their exceptional dedication and professionalism. 

Arepanrix and Pandemrix are trademarks of the GSK group of companies.

Clinical Characteristics of Coronavirus Disease 2019 in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

Activation of the endoplasmic reticulum stress sensor IRE1α by the vaccine adjuvant AS03 contributes to its immunostimulatory properties

Correlates of adjuvanticity: A review on adjuvants in licensed vaccines

Safety of AS03-adjuvanted influenza vaccines: A review of the evidence

Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, Guidance for Industry on Development and Licensure of Vaccines to Prevent COVID-19, in

Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine

Guideline on Repeated Dose Toxicity. CPMP/SWP/1042/99 Rev 1 Corr

International Conference on Harmonisation, Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals S5(R3), in

Organisation for Economic Co-operation Development

Guidance for Industry: Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications

World Health Organization, Guidelines on Nonclinical Evaluation of Vaccines

OECD series on principles of good laboratory practice and compliance monitoring

Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults

Detection of visceral alterations in mammalian fetuses

Methods for administering agents and detecting malformations in experimental animals

A note on the staining of the skeleton of cleared specimens with alizarin red S

Refinements in rapid clearing technic in the KOH-alizarin red S method for fetal bone

Bone development in laboratory mammals used in developmental toxicity studies

Maternal and neonatal characteristics and outcomes among COVID-19 infected women: An updated systematic review and meta-analysis

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

Dose site reactions and related findings after vaccine administration in safety studies

Chimeric hemagglutinin supra-seasonal universal influenza vaccine candidates administered sequentially by the intramuscular route are locally and systemically well-tolerated in rabbits

Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity

Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice

Intrauterine vertical transmissibility of SARS-CoV-2: the evidence is evolving

Retrospective Description of Pregnant Women Infected with Severe Acute Respiratory Syndrome Coronavirus 2

Analysis of SARS-CoV-2 vertical transmission during pregnancy

Risk of fetal death after pandemic influenza virus infection or vaccination

The maternal immune system during pregnancy and its influence on fetal development

Effects of influenza on pregnant women and infants

Impact of COVID-19 on maternal and neonatal outcomes: a systematic review and meta-analysis

Ducloy-Bouthors, Coagulation changes and thromboembolic risk in COVID-19 obstetric patients

Pre-eclampsialike syndrome induced by severe COVID-19: a prospective observational study

The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations

Pregnancy alters interleukin-1 beta expression and antiviral antibody responses during severe acute respiratory syndrome coronavirus 2 infection

Passive immunity in newborn from SARS-CoV-2-infected mother

Comprehensive analysis of COVID-19 during pregnancy

An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies

Should COVID-19 Mother Breastfeed her Newborn Child? A Literature Review on the Safety of Breastfeeding for Pregnant Women with COVID-19

Evaluation for SARS-CoV-2 in Breast Milk From 18 Infected Women

Antibodies in the breast milk of a maternal woman with COVID-19

Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19

Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants, medRxiv

Detection of breastmilk antibodies targeting SARS-CoV-2 nucleocapsid, spike and receptor-binding-domain antigens

Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action

Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons